• TriSalus Life Sciences

  Participated · Series B · Nov 2013

  TriSalus Life Sciences develops a drug delivery platform that includes devices using its proprietary Pressure-Enabled Drug Delivery (PEDD) approach and a clinical-stage investigational immunotherapy, nelitolimod. The company has two FDA-cleared devices: the TriNav® Infusion System for hepatic arterial infusion to liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is designed to modulate pressure and flow to deliver more therapeutic to tumors while reducing undesired delivery to normal tissue. Nelitolimod is intended to treat the immunosuppressive tumor environment that can limit current immunotherapies, and patient data from Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects. TriSalus plans to study nelitolimod delivered by PEDD across several indications where TLR9 is expressed and mechanical delivery barriers exist. The company works in partnership with leading cancer centers to advance its technology and clinical programs. Following the recent financing, TriSalus expects its cash runway to extend through 2025. Surefire Medical develops, manufactures and markets targeted delivery devices for the Interventional Oncology market centered on its Surefire Infusion System (SIS), a microcatheter with an expandable tip that increases infusion pressure and blocks backflow. The SIS is designed to deliver significantly more therapy into tumors while protecting healthy tissue. Clinical data cited include a randomized trial showing 68% improved tumor uptake and 58% decreased non-target delivery, a registry reporting 68% complete tumor response and 92% objective response, and a retrospective comparison showing a 79% versus 37% objective response for HCC. The company plans to use new financing to expand sales and marketing in the U.S. and Europe, initiate sales and clinical trials in China, and complete the 170-patient randomized QED trial (NCT02748161). Surefire is also pursuing opportunities in the $66B immunotherapy market, targeting site-specific delivery to solid tumors. The company is based in Westminster, Colo. Surefire Medical develops infusion and direct-to-tumor delivery systems for the interventional radiology and interventional oncology markets. Its flagship device, Surefire Precision, is specifically designed for targeted delivery in the treatment of primary liver cancer (HCC). The company is commercial stage and has received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand, Taiwan, Mexico and Brazil. Founded in 2009 and led by President and CEO James Chomas, the company is based in Westminster, Colorado. Surefire plans to use the new funding to support the global launch of Surefire Precision. It closed a $15M Series C in February 2015 to fund those commercial expansion efforts. Surefire Medical develops infusion systems designed to deliver embolic agents through a microcatheter using an expandable tip that collapses in forward flow and expands to the vessel wall in reverse flow. Its product family includes the Surefire Infusion System (ST, LT, mT) and specialty catheters. The company is commercial-stage and its devices have received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. Surefire intends to use the financing to expand product development, clinical trials, operations and marketing. The company was founded in 2009 and is led by CEO Jim Chomas. It is based in Westminster, Colorado.

No current team members are available.